PENTOSTATİN+ SİKLOFOSFAMİD+ RİTUKSİMAB(PCR) PROTOKOLÜ

Kaynaklar:

1-Flinn IW, Kopecky KJ, Foucar MK, Head D, Bennett JM, Hutchison R, Corbett W, Cassileth P, Habermann T, Golomb H, Rai K, Eisenhauer E, Appelbaum F, Cheson B, Grever MR. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood 2000. 96(9):2981-6.

2- Catovsky D, Matutes E, Talavera JG, O'Connor NT, Johnson SA, Emmett E, Corbett L, Swansbury J. Long term results with 2'deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 1994.14 Suppl 1:109-13.

3- Lathia C, Fleming GF, Meyer M, Ratain MJ, Whitfield L. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment. Cancer Chemother Pharmacol. 2002. 50(2):121-6.

4-Nicole Lamanna, Matt Kalaycio, Peter Maslak et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol . 2006 Apr 1;24(10):1575-81.

5- Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007 Jan;109(2):405–11.

6- Grever MR, Siaw MF, Jacob WF, Neidhart JA, Miser JS, Coleman MS, et al. The biochemical and clinical consequences of 2′-deoxycoformycin in refractory lymphoproliferative malignancy. Blood. 1981 Mar;57(3):406–17.

7- Weiss MA, Maslak PG, Jurcic JG, Scheinberg DA, Aliff TB, Lamanna N, et al. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003 Apr;21(7):1278–84.